TreatSMA response to the latest release of the MAA released by NICE today
At the CureSMA conference this year Biogen on 1st July 2019 published new results from the NURTURE study.
Following recent communication from the Scottish Government, the Scottish Medicines Consortium have now provided guidance that, as well as being available for those with SMA Type 1, from July 2019 nusinersen can be prescribed for those with SMA Types 2 and 3.
TreatSMA continues to work with NICE, NHSE and Biogen. We are seeking to expand inclusion if possible based on the recent appeal and campaign that TreatSMA and the community colaborated on together. TreatSMA and the community have made ITV News…